The second-generation TKI nilotinib and dasatinib were superior to imatinib in stimulating IFN-γ production in naïve and TEM γδT cells from CML patients (Fig. 5A, c). Here, IFNG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.